A new research paper was published in Volume 16 of Oncotarget on July 9, 2025, titled "A novel anti-human CD25 mAb with ...

Following the FDA ODD, European designation underscores ICT01’s potential as a ...

This could lead to the development of precision allergy treatments that are fast acting, needle free, and tailored to individual allergen sensitivities.

Approximately 40% of the European population are allergic to pollen, and their symptoms cause an estimated loss of 100 ...

A new research paper was published in Volume 16 of Oncotarget on July 9, 2025, titled “A novel anti-human CD25 mAb with ...

ImCheck’s ICT01 Receives FDA Orphan Drug Designation Clinical data showing unprecedented remission rates in newly diagnosed ...

Reports DescriptionAccording to the analysis conducted by Custom Market Insights (CMI), the Ultomiris drug market is ...

Improving antimicrobial stewardship through novel anti-infectives is the need of the hour: Dr Surendran: Shardul Nautiyal, ...

Astria Therapeutics' Navenibart shows promise in phase 3 trials for hereditary angioedema. Click here to find out why ATXS ...

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

The bispecific antibody market is experiencing rapid growth, primarily driven by the increasing prevalence of complex chronic diseases, such as cance ...